Replimune's Whiplash Week: How a Non-Interpretable FDA Filing Became a 10-3 Endorsement

Replimune shares double after FDA panel reverses 'non-interpretable' verdict, but data disputes and legal probes cloud the rally.

The distance between catastrophe and vindication in clinical-stage biotech can sometimes be measured in days. For Replimune, that journey took exactly 48 hours — and left investors holding a stock that has more than doubled in a single week while lawyers circle and analysts openly disagree on what comes next.

The Reversal That Reshaped the Trade

On July 28, the FDA released briefing documents for RP1, Replimune's melanoma candidate, branding the underlying IGNYTE study "non-interpretable." In the industry's informal lexicon, that phrasing has historically functioned as a death knell. The market responded accordingly: shares collapsed roughly 38% in a single session to $5.35, marking the worst trading day since April. It was the third setback for the drug, which had already been rejected by the agency once in 2025 and again in April 2026.

Then came the pivot. On July 30, the FDA's advisory committee voted 10-3 in favor of recommending approval for RP1 in advanced melanoma. The outcome caught many observers off guard — this was, after all, a candidate with two prior rejections on its record. Some industry watchers read the vote as evidence of a more accommodating posture within the current FDA leadership, one where clinical potential carries more weight than rigid statistical benchmarks.

A Rally With Conflicting Underpinnings

The market's response was unambiguous. Over the past seven trading sessions, the stock has surged 119.24%, with shares closing Tuesday at €10.56 after a more modest 2.08% daily gain. The stock traded at €10.39 on Wednesday, down 1.61% — a pullback that looks almost trivial against the preceding week's fireworks.

Yet beneath the surface of that rally sits a fundamental disagreement about what the data actually show. Replimune puts the patient response rate at 33.6%. The FDA's own analysis of the same study data arrived at just 15.7%. That chasm explains why the agency initially dismissed the study as unevaluable — and it remains a live source of uncertainty for investors even after the panel's favorable vote.

Wall Street Splits, Lawyers Circle

The analyst community reflects that ambiguity in starkly divergent price targets. Wedbush moved to "Neutral" following the late-July selloff, setting a target of $9. BMO Capital Markets, by contrast, rates the stock "Outperform" with a $16 target. The average analyst target currently sits at €10.41 — roughly 1.4% below the prevailing share price, suggesting the market has already priced in a substantial portion of a positive FDA outcome. Leerink analysts, for their part, now peg the probability of accelerated approval at 90%.

The violent price swings have also attracted legal scrutiny. Kirby McInerney LLP, along with Pomerantz, is investigating whether Replimune violated securities laws by failing to adequately disclose the risks surrounding the FDA's evaluation before the July 28 collapse. The firms are soliciting affected investors as they examine whether the company communicated the IGNYTE data transparently enough, soon enough.

A Benchmark for FDA Flexibility

With annualized 30-day volatility at 335.65% and a relative strength index of 60.9 — elevated but not yet in extreme overbought territory — this remains a stock for risk-tolerant traders rather than the cautious investor. The market capitalization of €816.44 million suggests the rally has room to extend or unwind depending on how the regulatory narrative develops.

The broader significance extends beyond Replimune itself. RP1 has effectively become a test case for how much interpretive flexibility the FDA will grant to complex, ambiguous clinical data going forward. Until the official PDUFA decision date arrives, the stock serves as a reminder of how quickly sentiment can shift in clinical biotech — in either direction. The extreme volatility of recent weeks is unlikely to subside while the core questions remain unresolved: whose reading of the data prevails, and whether the agency's final decision matches its advisory committee's recommendation.